FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096411032> ?p ?o ?g. }

• W2096411032 endingPage "359" @default.
• W2096411032 startingPage "352" @default.
• W2096411032 abstract "Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)1F receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT1D receptor, the prostanoid receptors EP2 and EP4, and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade. Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)1F receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT1D receptor, the prostanoid receptors EP2 and EP4, and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade." @default.
• W2096411032 created "2016-06-24" @default.
• W2096411032 creator A5023775224 @default.
• W2096411032 creator A5057969496 @default.
• W2096411032 date "2011-06-01" @default.
• W2096411032 modified "2023-10-10" @default.
• W2096411032 title "Emerging migraine treatments and drug targets" @default.
• W2096411032 cites W1708498915 @default.
• W2096411032 cites W18997466 @default.
• W2096411032 cites W1965821139 @default.
• W2096411032 cites W1966944990 @default.
• W2096411032 cites W1969289878 @default.
• W2096411032 cites W1972400251 @default.
• W2096411032 cites W1974501762 @default.
• W2096411032 cites W1975834524 @default.
• W2096411032 cites W1978308018 @default.
• W2096411032 cites W1982394915 @default.
• W2096411032 cites W1983647132 @default.
• W2096411032 cites W1986533271 @default.
• W2096411032 cites W1987355656 @default.
• W2096411032 cites W1992504770 @default.
• W2096411032 cites W1999527171 @default.
• W2096411032 cites W2007410119 @default.
• W2096411032 cites W2007412962 @default.
• W2096411032 cites W2008022422 @default.
• W2096411032 cites W2010242820 @default.
• W2096411032 cites W2011778887 @default.
• W2096411032 cites W2011893236 @default.
• W2096411032 cites W2013033676 @default.
• W2096411032 cites W2013095751 @default.
• W2096411032 cites W2013246061 @default.
• W2096411032 cites W2015650886 @default.
• W2096411032 cites W2018078088 @default.
• W2096411032 cites W2024556676 @default.
• W2096411032 cites W2026470025 @default.
• W2096411032 cites W2027337208 @default.
• W2096411032 cites W2028261667 @default.
• W2096411032 cites W2029253166 @default.
• W2096411032 cites W2029476307 @default.
• W2096411032 cites W2035615707 @default.
• W2096411032 cites W2036874023 @default.
• W2096411032 cites W2037009418 @default.
• W2096411032 cites W2037341378 @default.
• W2096411032 cites W2048132386 @default.
• W2096411032 cites W2049326326 @default.
• W2096411032 cites W2054998310 @default.
• W2096411032 cites W2055895292 @default.
• W2096411032 cites W2056550385 @default.
• W2096411032 cites W2059428990 @default.
• W2096411032 cites W2059818242 @default.
• W2096411032 cites W2062955354 @default.
• W2096411032 cites W2064236558 @default.
• W2096411032 cites W2065685736 @default.
• W2096411032 cites W2066871405 @default.
• W2096411032 cites W2066875663 @default.
• W2096411032 cites W2069043009 @default.
• W2096411032 cites W2071531614 @default.
• W2096411032 cites W2072463279 @default.
• W2096411032 cites W2076311390 @default.
• W2096411032 cites W2082901679 @default.
• W2096411032 cites W2083516978 @default.
• W2096411032 cites W2084241664 @default.
• W2096411032 cites W2084884436 @default.
• W2096411032 cites W2085794198 @default.
• W2096411032 cites W2086407360 @default.
• W2096411032 cites W2087386885 @default.
• W2096411032 cites W2090723133 @default.
• W2096411032 cites W2091319425 @default.
• W2096411032 cites W2093859355 @default.
• W2096411032 cites W2094826531 @default.
• W2096411032 cites W2098988727 @default.
• W2096411032 cites W2109139447 @default.
• W2096411032 cites W2117876332 @default.
• W2096411032 cites W2119011129 @default.
• W2096411032 cites W2121070581 @default.
• W2096411032 cites W2121282064 @default.
• W2096411032 cites W2123640336 @default.
• W2096411032 cites W2125197474 @default.
• W2096411032 cites W2125664611 @default.
• W2096411032 cites W2126194551 @default.
• W2096411032 cites W2129181629 @default.
• W2096411032 cites W2134747766 @default.
• W2096411032 cites W2135858080 @default.
• W2096411032 cites W2151599925 @default.
• W2096411032 cites W2153505330 @default.
• W2096411032 cites W2156723259 @default.
• W2096411032 cites W2162104155 @default.
• W2096411032 cites W2162942726 @default.
• W2096411032 cites W4211175391 @default.
• W2096411032 cites W4230120862 @default.
• W2096411032 doi "https://doi.org/10.1016/j.tips.2011.02.016" @default.
• W2096411032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21459461" @default.
• W2096411032 hasPublicationYear "2011" @default.
• W2096411032 type Work @default.
• W2096411032 sameAs 2096411032 @default.
• W2096411032 citedByCount "62" @default.
• W2096411032 countsByYear W20964110322012 @default.
• W2096411032 countsByYear W20964110322013 @default.

• next